GO
Loading...

Enter multiple symbols separated by commas

Medicine

More

  • June 29- Vitae Pharmaceuticals Inc said its drug to treat type 2 diabetes in overweight patients did not meet its main goal in a mid-stage study testing it as an add-on therapy. The American Diabetes Association estimates that as many as 1 in 3 American adults will have type 2 diabetes by 2050.. Still, through Friday's close of $15.19, Vitae's shares have almost...

  • June 29- Egalet Corp said data showed its experimental painkiller was less likely to be abused than a form of morphine already being sold. A study showed recreational opioid users did not like and were less prone to snort the company's painkiller, Egalet -001, than MS Contin. Egalet's study results come a week before a panel of experts advising the U.S. Food and...

  • June 29- Vitae Pharmaceuticals Inc said its drug to treat type 2 diabetes in overweight patients did not meet its main goal in a mid-stage study testing it as an add-on therapy. The drug, being co-developed with German drugmaker Boehringer Ingelheim, was tested as an add-on therapy to metformin, a commonly prescribed diabetes drug. Results from another trial...

  • Bristol-Myers to stop new antiviral drug research Thursday, 25 Jun 2015 | 11:08 AM ET

    June 25- Bristol-Myers Squibb said on Thursday that it would stop efforts to find new antiviral drugs and cut 100 related jobs. The company said a research facility is expected to open in Cambridge, Massachusetts in 2018 and that the expansion of an R&D site in San Francisco Bay Area is likely to be completed by 2016.. Bristol-Myers' stock was up marginally at...

  • Bristol-Myers Squibb to shift research jobs Thursday, 25 Jun 2015 | 10:59 AM ET

    HARTFORD, Conn.— Bristol-Myers Squibb Co. will expand its presence in research centers in Cambridge, Massachusetts, and San Francisco, as it cuts jobs in Connecticut, the biopharmaceutical company announced Thursday. The New York- based company will open a research site in Cambridge— home to the Massachusetts Institute of Technology and Harvard— in 2018 and...

  • Health care stocks surge as investors cheer ruling Thursday, 25 Jun 2015 | 10:42 AM ET
    Protesters outside the Supreme Court on March 4, 2015.

    See how major health care industry stocks are responding to the Supreme Court's Obamacare ruling.

  • INDIANAPOLIS— Eli Lilly received some European legal backing for its top product, the lung cancer treatment Alimta, on Thursday when a British court upheld a patent protecting a vitamin regimen administered with the drug. Shares of the Indianapolis drugmaker climbing in premarket trading. Alimta brought in $2.79 billion in sales globally last year as...

  • Panel gives weak endorsement of new meningitis shots Wednesday, 24 Jun 2015 | 12:44 PM ET

    NEW YORK— A federal panel gave a weak endorsement Wednesday to two expensive meningitis shots, declining to recommend that all teens get the vaccine and leaving the decision to parents and doctors. At a meeting in Atlanta, the panel approved a half-measure that says older teens and young adults may get the shots— if they and their parents want to take that step.

  • June 24- AbbVie Inc said on Wednesday that its hepatitis C cocktail Viekira Pak was effective whether or not it was used in combination with the compound ribavirin against the most common form of the disease, according to data from a late-stage study. All the patients in the study showed a sustained response to Viekira Pak as a standalone treatment after 12 weeks...

  • AbbVie hepatitis C cocktail succeeds in late-stage study Wednesday, 24 Jun 2015 | 6:19 AM ET

    June 24- AbbVie Inc said on Wednesday that all patients in a late-stage study showed a sustained response to its cocktail of hepatitis C treatments, currently sold in the U.S. as Viekira Pak.

  • June 23- Medtronic Inc said it was recalling certain lots of its of its tracheostomy tubes, devices used to ease breathing, after receiving complaints, including reports of 12 serious injuries. The medical device maker said it began notifying hospitals and distributors on May 8 that affected lots of its Covidien Shiley tracheostomy tubes were formed with a...

  • June 22- Cancer drug developers Kite Pharma Inc and Bluebird Bio Inc said they would partner to develop and market a new class of T-cell therapies for HPV-associated cancers. The National Cancer Institute has indicated that cell therapies could eventually become the standard of care in the multi-billion market to treat cancer. Juno Therapeutics Inc, another...

  • June 22- Cancer drug developers Kite Pharma Inc and Bluebird Bio Inc said they would partner to develop and market T-cell therapies for HPV-associated cancers. T-cell receptors are a class of compounds that make it easier for the body's immune cells to mainly identify and then destroy cancer cells. Human papillomavirus is the most common viral infection of...

  • Tekmira says Ebola drug unlikely to work in study Friday, 19 Jun 2015 | 5:44 PM ET

    NEW YORK— Shares of drugmaker Tekmira slumped Friday after the company said it stopped enrolling new patients in a trial of a treatment for a strain of Ebola. The company's shares dropped $1.74, or 11.6 percent, to $13.28 on Friday. Tekmira Pharmaceuticals Corp. calls the drug TKM-Ebola-Guinea and it is designed to target the strain of the virus that is...

  • Biotech to break out, buy these names: Analyst Friday, 19 Jun 2015 | 3:19 PM ET
    Biotech research

    Biotech is going to break out, RBC Capital Markets' Michael Yee said. There are the names on his buy list.

  • Microbiome studies changing human health Friday, 19 Jun 2015 | 8:33 AM ET
    Microbiome changing human health

    CNBC's Meg Tirrell explains what the microbiome is and why it's medicines new frontier.

  • Gilead still has China patent for active compound. NEW YORK/ SHANGHAI, June 19- China has rejected a Gilead Sciences Inc patent application related to its costly hepatitis C drug, a U.S. advocacy group said, adding the move may lead to other countries to consider rejecting patents for the controversial treatment. Gilead, however, holds the China patent to the base...

  • June 19- China has rejected Gilead Sciences Inc's application for a new patent related to its costly hepatitis C drug Sovaldi, removing a potential barrier to generic versions of the drug there, a U.S. legal group announced on Friday. Gilead still has a patent in China on sofosbuvir, the main ingredient of Sovaldi, a highly effective treatment for hepatitis C which...

  • Insurer mergers may be 'dangerous': Mt. Sinai CEO Thursday, 18 Jun 2015 | 6:05 PM ET
    Signage hangs outside Mount Sinai Hospital on August 4, 2014 in New York City.

    Consolidation in the health insurance industry is "potentially dangerous" for the hospital business, Mount Sinai Health System's CEO said Thursday.

  • June 18- Amgen Inc said its drug met the main goal of improving overall survival in metastatic colorectal cancer patients who have not responded to chemotherapy. The U.S. Food and Drug Administration approved Vectibix in 2006 as a standalone treatment for metastatic colorectal cancer. Colorectal cancer affects about 1.2 million people worldwide each year,...